MSH2 and cancer: By disregarding individuals with MSH6 and PMS2 mutations, where cancer risk is significantly lower, and selecting only individuals with MLH1, MSH2 or EPCAM mutations, where lifetime colorectal cancer risk is approximately 50%, we were able to perform our comparative study in a relatively homogeneous population.